Core Points - SureNano Science Ltd. has granted 1,500,000 stock options to various directors, officers, and consultants, which will vest immediately and can be exercised at CAD $0.18 per share for a period of 5 years [1] - Following this grant, the total stock options represent 4.4% of the outstanding common shares of the Company [2] Company Overview - SureNano Science Ltd. specializes in the sale and distribution of the SureNano™ surfactant, a food-grade compound that enables the creation of high-performance nano-emulsions, enhancing product stability, bioavailability, clarity, and taste [3] - The Company holds an exclusive license to distribute the SureNano™ surfactant in Canada and Colorado, USA [3]

Vancouver, British Columbia--(Newsfile Corp. - December 10, 2025) - SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) (the "Company" or "SureNano") is pleased to announce, as a follow-up to its news release dated November 5, 2025, that it has closed its non-brokered private placement to raise $1,250,000 through the issuance of 10,000,000 units (each a "Unit") at a price of $0.125 per Unit. Each Unit is comprised of one common share (a "Common Share") and one Common Share purchase warrant (each a "Warrant"), ...

Core Viewpoint - SureNano Science Ltd. has entered into a non-binding letter of intent with GlucaPharm Inc. to explore a proposed transaction for the development of a GLP-1 drug, GEP-44, which targets diabetes and weight loss with a no-needle administration method and improved tolerability [1][2] Proposed Transaction Overview - The proposed transaction is structured as a share exchange, where SureNano will acquire 100% of GlucaPharm's common shares, with GlucaPharm shareholders expected to own under 20% of SureNano's shares post-transaction [3][4] - The transaction is subject to customary due diligence, negotiation of a definitive agreement, and necessary regulatory approvals [4] GlucaPharm's Product Details - GlucaPharm holds exclusive rights to develop GEP-44, a novel GLP-1 compound that aims to improve treatment for obesity and diabetes, showing strong preclinical results and academic validation [2] Private Placement - SureNano announced a private placement to raise up to $1,250,000 by selling up to 10,000,000 units at $0.125 per unit, with each unit consisting of one common share and one warrant [6][7] - Proceeds from the private placement will be used for operating expenses, including legal fees and market exploration, and are not dependent on the acquisition of GlucaPharm [8] Company Background - SureNano Science Ltd. specializes in the sale and distribution of the SureNano™ surfactant, which enhances the performance of nanoemulsions, and holds exclusive distribution rights in Canada and certain U.S. states [9]

Core Viewpoint - SureNano Science Ltd. is planning a private placement to raise up to $1,250,000 through the sale of units, which will include common shares and purchase warrants [1][2]. Group 1: Private Placement Details - The private placement will consist of up to 10,000,000 units priced at $0.125 each, with each unit comprising one common share and one warrant [2]. - Each warrant allows the holder to purchase one common share at $0.35 for 24 months, with an acceleration provision if the share price exceeds $0.50 for ten consecutive trading days [2]. - Finders introducing subscribers may receive a 6% cash commission and 6% in common share purchase warrants, also exercisable at $0.35 for 24 months [3]. Group 2: Use of Proceeds - Proceeds from the private placement will be allocated for operating expenses, including legal and audit fees, and general working capital [3]. - The company aims to explore new markets for its SureNano™ surfactant and investigate complementary industries [3]. Group 3: Company Overview - SureNano Science Ltd. specializes in the sale and distribution of the SureNano™ surfactant, a food-grade compound for high-performance nanoemulsions [5]. - The company holds an exclusive license to distribute the SureNano™ surfactant in Canada, Oklahoma, and Colorado [5].

Vancouver, British Columbia--(Newsfile Corp. - September 19, 2025) - SURENANO SCIENCE LTD. (CSE: SURE) (OTCQB: SURNF) (the "Company" or "SureNano") announces that it has closed a private placement financing of 2,450,000 common shares at a price of $0.10 per share. Total proceeds of $245,000 were received by the Company, including $85,000 in debt conversion. The Company intends to use the cash proceeds for operating expenses, including legal and audit fees and general working capital. No part of the proceed ...